tirzepatide surmount 2 Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Tirzepatide for the treatment of

Compare the numbers: What GLP-1 programs actually cost per month Approximately 73% of American adults seeking GLP-1 therapy face barriers related to insurance coverage or cost

Li K, Li W, Huang Y

New Agents Aside from GLP-1RA, GIP agonism is also a promising treatment for obesity, with preclinical studies demonstrating improved metabolic profiles and reduced food intake

Improved weight loss sustainability Perhaps the most significant long-term benefit is what happens when semaglutide is eventually stopped

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor

As a result, building long-term habits is the focus of a lot of treatment talk from healthcare providers